Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTSTEP-HF: Sacubitril/Valsartan vs Enalapril on Physical Activity
NCT02900378Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Primary endpoints: Six Minute Walk Test at 12 weeks and Mean Daily Non-sedentary Daytime Activity at 12 weeks. Started Dec 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02900378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900378.